Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Synthetic Peptide Non-Covalently Transports Cancer Drugs Across the Blood-Brain Barrier

By BiotechDaily International staff writers
Posted on 18 Jun 2014
Cancer researchers have used a novel synthetic peptide to transport chemotherapeutic compounds and other small molecules across the blood-brain barrier and into the brains of mice.

The transport peptide, K16ApoE, comprised sixteen lysine residues and 20 amino acids corresponding to the LDLR (low density lipoprotein receptor)-binding domain of apolipoprotein E (ApoE). Investigators at the Mayo Clinic (Rochester, MN, USA) had demonstrated previously that by mimicking a ligand-receptor system, K16ApoE could deliver three different proteins (beta-galactosidase, IgG, and IgM) in a non-covalent fashion across the blood-brain barrier. To their knowledge this was the first report demonstrating successful delivery of various proteins across the blood-brain barrier that did not involve chemically linking the proteins with a carrier entity.

In the current study, the investigators delivered chemotherapeutics and other agents into the brains of mice either by injecting the carrier peptide and the drugs separately or as a mixture via the femoral vein. A modification of the method comprised injection of K16ApoE pre-mixed with cetuximab, followed by injection of a small-molecule drug.

The investigators reported in the May 21, 2014, online edition of the journal PLOS ONE that seven-of-seven different small molecules were successfully delivered to the brain via K16ApoE. Depending on the injection method, brain uptake was 34–50-fold greater for cisplatin and 54–92-fold greater for methotrexate with K16ApoE than without. Visually intense brain-uptake of the dyes Evans Blue, Light Green SF, and Crocein scarlet was also achieved. Direct intracranial injection of Evans Blue showed locally restricted distribution of the dye in the brain, whereas K16ApoE-mediated intravenous injection resulted in the distribution of the dye throughout the brain.

"We know that some chemotherapeutic agents can kill brain tumor cells when they are outside the brain (as in a laboratory test). But because the agents cannot cross the blood-brain barrier, they are not able to kill brain tumor cells inside the brain. With the peptide carrier, these agents can now get into the brain and potentially kill the tumor cells," said senior author Dr. Robert Jenkins a neurology researcher at the Mayo Clinic.

Related Links:

Mayo Clinic



Channels

Drug Discovery

view channel
Image: Cancer cells were treated with a control (left) and the overstimulating compound MCB-613 (right) (Photo courtesy of Dr. Lei Wang, Baylor University College of Medicine).

Drug Candidate Propels Cancer Cells into Fatal Overdrive

A candidate drug that destroys cancer cells by stimulating them to produce more proteins than the cells can actually process was shown to kill a wide variety of cancer cells in culture and to inhibit tumor... Read more

Lab Technologies

view channel
Image: The Synergy Neo2 Multi-Mode Reader recently received Cisbio HTRF certification (Photo courtesy of BioTek Instruments Inc.).

High-Speed Multimode Microplate Reader Receives Homogenous Time-Resolved Fluorescence Certification

A new high-performance, high-speed microplate reader has received HTRF (homogenous time-resolved fluorescence) accreditation that certifies that it complies with standards for detection set by a major... Read more

Business

view channel

Innovative Microbial Diagnostics Developer Acquired by Biomedical Giant

A biotech company noted for its development of innovative products in the field of molecular microbiology diagnostics has been acquired by one of the world's largest biomedical corporations. GeneWEAVE BioSciences, Inc.(Los Gatos, CA, USA) and Roche (Basel, Switzerland) have announced that Roche will be purchasing the... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.